AGA Family of Websites: Gastro.org
Guideline

Guideline update for prevention and treatment of hepatitis B reactivation

AGA's clinical practice guideline addresses prevention and management of hepatitis B virus reactivation (HBVr) for the growing number of patients on immunosuppressive drugs.

Guideline Tool kits

Members only access the guideline tool kits

Recommendations

AGA published the first guideline on preventing and managing HBVr among individuals on immunosuppressive therapy in 2014. Since that publication, multiple novel classes of immunosuppressive therapies have been developed and approved for clinical use. Additionally, interventional therapies, such as transcatheter arterial chemoembolization (TACE), that can induce an immunosuppressed state and thus are relevant to potential HBVr, have also been recognized. This 2025 guideline aims to address the wide range of exposures that are suspected to increase the risk of HBVr and for which guideline recommendations currently do not exist. In particular, the 2025 guideline sought to provide guidance on the prevention and management of HBVr in individuals taking immune checkpoint inhibitors, anti-interleukin therapies, chimeric antigen receptor T (CAR-T) cell therapies, cytokine/intergrin inhibitor therapies, tyrosine kinase inhibitors (TKIs), antiT-cell therapies, Janus kinase (JAK) inhibitors, and update the guidance provided for anti-TNF therapies in light of new evidence. The 2025 guideline also sought to provide guidance on the prevention and management of HBVr among individuals undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) and individuals who are co-infected with hepatitis C virus (HCV) and undergoing a direct-acting antiviral (DAA) treatment. These recommendations are not intended to dictate medical decision-making but are intended to provide evidence-based guidance to inform medical decision-making. No single guideline can encompass the nuance of medical decision-making that requires clinical judgment and contextualization of medical knowledge by individual values and preferences. Within this context, this guideline aims to provide guidance on the benefits and harms of antiviral prophylaxis and monitoring for HBVr as alternative strategies.  

Resources

Your hub for GI education

Discover upcoming events, webinars and other education to stay current with advances in the GI field.

The most trustworthy clinical guidance comes from AGA.

Want the latest clinical guidance to help you take care of patients? AGA members get first access to updates and clinical resources.

X